Molecular Therapy-Nucleic Acids

Molecular Therapy-Nucleic Acids (Mol Ther-Nucl Acids, ISSN: 2162-2531) is a leading open-access, peer-reviewed journal published by Cell Press on behalf of the American Society of Gene and Cell Therapy. The journal is dedicated to the rapid dissemination of high-quality research on the development, mechanisms, and therapeutic applications of nucleic acid-based molecules, including antisense oligonucleotides, siRNAs, microRNAs, aptamers, mRNA therapeutics, gene editing constructs, and non-coding RNAs. Its scope encompasses both basic science and translational studies, with a particular emphasis on nucleic acid chemistry, delivery systems, immunogenicity, and preclinical and clinical validation. The journal publishes original research articles, comprehensive reviews, and brief communications, offering a dedicated platform for the nucleic acid subfield within the broader gene therapy community. Target audiences include molecular biologists, pharmacologists, geneticists, bioengineers, and clinicians focused on RNA-based therapeutics and gene modulation. A notable feature is its fully open-access model, ensuring global accessibility and compliance with funder mandates, coupled with rigorous peer review and rapid publication times. The journal holds a 2026 Journal Impact Factor of 8.800 and is consistently ranked in the JCR Q1 quartile within both Biotechnology & Applied Microbiology and Genetics & Heredity categories, reflecting its strong standing as a top-tier specialty journal in the competitive landscape of nucleic acid and gene therapy research.